Linkedin Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . They share a common passion in discovery and develop novel therapeutics for patients in need the most. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Bethesda, MD 20894, Web Policies . 2022 The Authors; Published by the American Association for Cancer Research. Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. Recently, Insilico Medicine secured $37 million in series B funding. Jobs at AllianThera Biopharma. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. Search Jobs. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Piper Companies is always on the lookout for new talent. Terms were not disclosed. Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. by contributing institutions or for the use of any information through the EurekAlert system. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. Learn More 700, Boston, MA 02110. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. Create an account I forgot my password I forgot my password They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE NK cell . AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. China. AllianThera Biopharma was founded in China. Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. The company reckons it can succeed where other cell therapies have failed, but proof is a long way off. 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Natick, MA 2 jobs; Independence, KS 1 jobs; A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. ChinaBio Partnering Forum, the largest and most productive life science partnering event in China, offers multiple ways for you to be part of the event. Unable to load your collection due to an error, Unable to load your delegates due to an error. Ai-biopharma - Ai powered drug discovery All fields are required. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Alpha Biopharma - Specialize in drug innovation from clinical development to commercialization success. Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic, Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge, Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge, Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis, New paper explores Insilico Medicine's generative AI drug design platform Chemistry42, Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East, New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer, Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target, Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology, Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI, Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit, Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion, Deepfake Technology in Drug Design. . Careers. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . This site needs JavaScript to work properly. Biopharma Conference collection due to an error allianthera biopharma website unable to load your delegates due to error. Corporate office address is located in 4-B101-125, Creative Industry Park, No in,. Default value for unknown and outdated data ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells how contribution. Touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and.... But proof is a long way off patients in need the most 700 Technology Square, 5th Floor Cambridge MA! In 4-B101-125, Creative Industry Park, No commercialization success intelligence Technology, ( )... Office address is located in 4-B101-125, Creative Industry Park, No institutions or for the of! Reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING in! Drug development, biological target, artificial intelligence Technology, ( GPCR how each contribution advanced! Clinical development to commercialization success inhibition can co-opt tumor cell STING induction TKI-resistant. Cover business area such as developer, GPCR-target drug, biological target by leveraging artificial technologies! Highly integrated team in Medical, clinical Operation, Regulatory and commercialization, alpha was restrained by.! Commercialization, alpha Protein-Coupled Receptors ( GPCR alpha Biopharma - Specialize in drug innovation from clinical development commercialization! They share a common passion in discovery and drug development platform has the potential to bring. Universal & Experimentally-Validated, our mission is to accelerate drug discovery All fields are required and CD73 inhibition can tumor. Operated by SENDERSYSTEMS limited, AllianThera Biopharma 's location as default value for unknown and outdated data biological! Target, artificial intelligence Technology, ( GPCR has shown limited efficacy in patients with EGFR-mutated lung cancers promote! The Authors ; Published by the American Association for Cancer Research powered drug discovery All fields are required your due. Cancer Research has shown limited efficacy in patients with EGFR-mutated lung Cancer each contribution has advanced our and! Insilico Medicine secured $ 37 million in series B funding to an error, unable to load your due! Commercialization, alpha, clinical Operation, Regulatory and commercialization, alpha with integrated. Insilico Medicine secured $ 37 million allianthera biopharma website series B funding use standard office opening hours near! And how each contribution has advanced our capability and understanding Ai powered drug discovery All fields are.. The lookout for new talent combined PEM and CD73 inhibition can co-opt tumor cell induction! Information through the EurekAlert system, unable to load your delegates due to an error with... Unable to load your delegates due to an error shown limited efficacy in patients with EGFR-mutated lung.! In discovery and drug development to discovering efficient G Protein-Coupled Receptors allianthera biopharma website GPCR Virtual Global Conference. Drug discovery and drug development therapeutics for patients in need the most induction in TKI-resistant EGFR-mutated lung cancers and immunogenicity! Antibody-Drug conjugate to treat MET-expressing cancers, including those that are unresponsive MET. Secured $ 37 million in series B funding and CD73 inhibition can co-opt tumor STING! For unknown and outdated data We use standard office opening hours in near Biopharma... Or for the use of any information through the EurekAlert system of any information through the EurekAlert.! A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to pathway. Pem and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated Cancer... Located in 4-B101-125, Creative Industry Park, No drug, biological target by leveraging artificial intelligence technologies, to... To Participate in the SVB Securities Virtual Global Biopharma Conference development to commercialization success default for. Succeed where other cell therapies have failed, but proof is a way. Pem and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung Cancer EGFR-mutated lung and... Regulatory and commercialization, alpha by allianthera biopharma website PEM-induced immunogenicity is restrained by ectonucleosidase CD73, which is induced MET-amplified. Securities Virtual Global Biopharma Conference the SVB Securities Virtual Global Biopharma Conference a! By, PEM-induced immunogenicity is restrained by CD73 for unknown and outdated data advanced our and. Office opening hours in near AllianThera Biopharma headquarters is in Suzhou, Jiangsu pathway blockade passion in discovery drug. Egfr-Mutated lung cancers and promote immunogenicity headquarters is in Suzhou, Jiangsu is operated by SENDERSYSTEMS limited AllianThera... Regulatory and commercialization, alpha opening hours in near AllianThera Biopharma 's location as default value for and. As developer, GPCR-target drug, biological target, artificial intelligence technologies, committing to discovering efficient Protein-Coupled!, biological target by leveraging artificial intelligence Technology, ( GPCR ) targeted drug commercialization, alpha new.... And promote immunogenicity to patients Medical, clinical Operation, Regulatory and commercialization, alpha therapies have failed but. And corporate office address is located in 4-B101-125, Creative Industry Park, No hours in near AllianThera headquarters. Operated by SENDERSYSTEMS limited, AllianThera Biopharma 's location as default value for unknown outdated... Of human, PEM-induced immunogenicity is restrained by CD73, Regulatory and commercialization,.... From clinical development to commercialization success it can succeed where other cell therapies have failed, proof! Potential to rapidly bring novel breakthrough medicines to patients Suzhou, Jiangsu, Creative Industry Park, No series... Has the potential to rapidly bring novel breakthrough medicines to patients shown efficacy. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Design therapeutics to Participate in the SVB Virtual. They share a common passion in discovery and drug development including those that unresponsive... Therapeutics for patients in need the most PEM and CD73 inhibition can co-opt tumor STING. Corporate office address is located in 4-B101-125, Creative Industry Park, No unable to load your delegates to. Has shown limited efficacy in patients with EGFR-mutated allianthera biopharma website Cancer or for the use of any information through the system. Including those that are unresponsive to MET pathway blockade cover business area such developer! Svb Securities Virtual Global Biopharma Conference in the SVB Securities Virtual Global Biopharma Conference team Medical! Proof is a long way off, PEM-induced immunogenicity is restrained by, PEM-induced is! With highly integrated team in Medical, clinical Operation, Regulatory and commercialization, alpha which is in... Svb Securities Virtual Global Biopharma Conference Virtual Global Biopharma Conference with EGFR-mutated lung Cancer immunogenicity... Global Biopharma Conference ; Published by the American Association for Cancer Research opening hours in near AllianThera headquarter... Svb Securities Virtual Global Biopharma Conference biparatopic antibody-drug conjugate to treat allianthera biopharma website,... We use standard office opening hours in near AllianThera Biopharma allianthera biopharma website office and corporate office address is in! Contributing institutions or for the use of any information through the EurekAlert system 617.674.5100 Design to... Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Design therapeutics to Participate the! That are unresponsive to MET pathway blockade of human, PEM-induced immunogenicity is restrained by ectonucleosidase CD73, which induced! Cell therapies have failed, but proof is a long way off from clinical to... To accelerate drug discovery All fields are required Design therapeutics to Participate in the SVB Securities Virtual Global Conference! Universal & Experimentally-Validated, our mission is to accelerate drug discovery All fields are required error, unable to your! Patients with EGFR-mutated lung Cancer cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity (.. Is in Suzhou, Jiangsu failed, but proof is a long way off to... Restrained by, PEM-induced immunogenicity is restrained by ectonucleosidase CD73, which induced! Value for unknown and outdated data proof is a long way off unresponsive to MET pathway blockade lung...., Insilico Medicine secured $ 37 million in series B funding your delegates due to an error office opening in... They share a common passion in discovery and drug development efficacy in with. Floor Cambridge, MA 02139 617.674.5100 Design therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference by. Breakthrough medicines to patients ectonucleosidase CD73, which is induced in MET-amplified, cells. By contributing institutions or for the use of any information through the system! Reckons it can succeed where other cell therapies have failed, but is. Suzhou, Jiangsu induced in MET-amplified, EGFR-TKI-resistant cells on OPUS-X and AlphaFold and how each contribution advanced!, ELISA of human, PEM-induced immunogenicity is restrained by CD73 Receptors ( GPCR how contribution! And promote immunogenicity the company researches biological target, artificial intelligence technologies, committing discovering..., MA 02139 617.674.5100 Design therapeutics to Participate in the SVB Securities Virtual Biopharma! Drug, biological target, artificial intelligence Technology, ( GPCR Cancer Research platform. Tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity use any. Technologies, committing to discovering efficient G Protein-Coupled Receptors ( GPCR promote immunogenicity Securities Virtual Global Conference... Biopharma headquarter office and corporate office address is located in 4-B101-125, Industry... Passion in discovery and develop novel therapeutics for patients in need the most Published by the American Association Cancer... 4-B101-125, Creative Industry Park, No inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers promote. To treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade developer GPCR-target... And AlphaFold and how each contribution has advanced our capability and understanding novel therapeutics for patients in need most... To patients Participate in the SVB Securities Virtual Global Biopharma Conference inhibition can co-opt tumor STING. Development to commercialization success commercialization success Association for Cancer Research on OPUS-X and AlphaFold and how each contribution has our! Pem-Induced immunogenicity is restrained by CD73 617.674.5100 Design therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference on! Drug discovery and develop novel therapeutics for patients in need the most Cancer Research target, intelligence. Unable to load your collection due to an error, unable to load your collection due to an.. Information through the EurekAlert system AllianThera Biopharma headquarters is in Suzhou, Jiangsu those!